PlasmaTech Biopharmaceuticals, a biopharmaceutical company advancing patient care in critical areas, has announced that Stephen T. Sonis, DMD, DMSc, has joined its scientific advisory board (SAB). A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Sonis has collaborated with management in recent years on advancing the company's clinical efforts of its oral mucositis treatment, MuGard.
"We are grateful that Sonis has joined our SAB," said Scott Schorer, CEO of PlasmaTech Biopharmaceuticals. Sonis is a formative force in the evolution of mucositis treatments, and his ability to provide us with critical insight has served as the cornerstone of our MuGard commercialization efforts. His counsel will continue to be highly valuable to us as we advance additional products from our Polymer Hydrogel Technology (PHT) platform, such as ProctiGard."
Sonis currently is clinical professor of oral medicine at Harvard School of Dental Medicine, senior surgeon and chief, divisions of oral medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and as chief scientific officer of Biomodels. He also is a consultant to a number of biotechnology and pharmaceutical companies, advising directly on the conduct of clinical trials of oral mucositis.